The company said shareholders approved the Share Issuance Proposal at the special meeting held on January 27, 2026, with 53,910,265 votes for, 136,468 against and 25,377 abstaining.

1. 01

   The company said shareholders approved the Share Issuance Proposal at the special meeting held on January 27, 2026, with 53,910,265 votes for, 136,468 against and 25,377 abstaining.

2. 02

   Waters said about 54,072,110 shares of its common stock were present or represented by proxy at the special meeting, representing approximately 90.80% of all Waters common stock entitled to vote.

3. 03

   Waters said it entered into a Merger Agreement and a Separation Agreement on July 13, 2025, under which BD's Biosciences and Diagnostic Solutions business will be spun off to SpinCo in a Reverse Morris Trust transaction and SpinCo will become a wholly owned subsidiary of the company.

4. 04

   The company said the transaction is expected to close on February 9, 2026, subject to the satisfaction or waiver of the remaining customary closing conditions. It said BD has received a Private Letter Ruling and all required regulatory approvals.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.